The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Open accessAbstract
// Young Kwang Chae 1,2,3,* , Keerthi Ranganath 3,* , Peter S. Hammerman 4 , Christos Vaklavas 5 , Nisha Mohindra 1,2,3 , Aparna Kalyan 1,2,3 , Maria Matsangou 1,2,3 , Ricardo Costa 1 , Benedito Carneiro 1,2,3 , Victoria M. Villaflor 1,2,3 , Massimo Cristofanilli 1,2,3 and Francis J. Giles 1,2,3 1 Developmental Therapeutics Program of the Division of Hematology Oncology, Chicago, IL, USA 2 Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA 3 Northwestern University Feinberg School of Medicine, Chicago, IL, USA 4 Dana Farber Cancer Institute, Boston, MA, USA 5 Division of Hematology Oncology, University of Alabama Birmingham, Birmingham, AL, USA * These authors have contributted equally to this work Correspondence to: Young Kwang Chae, email: // Keywords : fibroblast growth factor receptor inhibition Received : September 24, 2016 Accepted : November 22, 2016 Published : December 22, 2016 Abstract The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase signaling pathway that has a fundamental role in many biologic processes including embryonic development, tissue regeneration, and angiogenesis. Increasing evidence indicates that this pathway plays a critical role in oncogenesis via gene amplification, activating mutations, or translocation in tumors of various histologies. With multiplex sequencing technology, the detection of FGFR aberrations has become more common and is tied to cancer cell proliferation, resistance to anticancer therapies, and neoangiogenesis. Inhibition of FGFR signaling appears promising in preclinical studies, suggesting a pathway of clinical interest in the development of targeted therapy. Phase I trials have demonstrated a manageable toxicity profile. Currently, there are multiple FGFR inhibitors under study with many non-selective (multi-kinase) inhibitors demonstrating limited clinical responses. As we progress from the first generation of non-selective drugs to the second generation of selective FGFR inhibitors, it is clear that FGFR aberrations do not behave uniformly across cancer types; thus, a deeper understanding of biomarker strategies is undoubtedly warranted. This review aims to consolidate data from recent clinical trials with a focus on selective FGFR inhibitors. As Phase II clinical trials emerge, concentration on patient selection as it pertains to predicting response to therapy, feasible methods for overcoming toxicity, and the likelihood of combination therapies should be utilized. We will also discuss qualities that may be desirable in future generations of FGFR inhibitors, with the hope that overcoming these current barriers will expedite the availability of this novel class of medications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“In fact, the most common acquired EGFR mutation leading to decreased survival has been found to be the “gatekeeper” mutation T790M [129], with nearly 50-60% of resistant cases demonstrating this anomaly [130].”
BackgroundWatterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Hunter, D. J., Kraft, P., Jacobs, K. B., Cox, D. G., Yeager, M., Hankinson, S. E., Wacholder, S., Wang, Z., Welch, R., Hutchinson, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2075 · Cited by 1,481
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3212 · Cited by 808
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Seiwert, T. Y., Zuo, Z., Keck, M. K., Khattri, A., Pedamallu, C. S., Stricker, T., Brown, C., Pugh, T. J., Stojanov, P., Cho, J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3310 · Cited by 657
Self-citationChesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.019 · Cited by 555
Arai, Y., Totoki, Y., Hosoda, F., Shirota, T., Hama, N., Nakamura, H., Ojima, H., Furuta, K., Shimada, K., Okusaka, T., et al. (2014) · Hepatology · doi:10.1002/hep.26890 · Cited by 553
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., Schmid, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 477
Pietras, K., Pahler, J., Bergers, G., & Hanahan, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050019 · Cited by 453
Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3.
Keegan, K., Johnson, D. E., Williams, L. T., & Hayman, M. J. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.4.1095 · Cited by 411
Dieci, M. V., Arnedos, M., Andre, F., & Soria, J. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0362 · Cited by 406
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Tabernero, J., Bahleda, R., Dienstmann, R., Infante, J. R., Mita, A., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7341 · Cited by 388
CAM-FGF Receptor Interactions: A Model for Axonal Growth
Doherty, P., & Walsh, F. S. (1996) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.1996.0049 · Cited by 379
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Ignatiadis, M., Lee, M., & Jeffrey, S. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1190 · Cited by 355
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Werner, S., Duan, D. S., de Vries, C., Peters, K. G., Johnson, D. E., & Williams, L. T. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.1.82 · Cited by 338
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Wang, S., Cang, S., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0268-z · Cited by 302
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis
Lieu, C., Heymach, J., Overman, M., Tran, H., & Kopetz, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0659 · Cited by 286
Wang, Y., & Becker, D. (1997) · Nature Medicine · doi:10.1038/nm0897-887 · Cited by 284
Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4
Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., & Donoghue, D. J. (2000) · Oncogene · doi:10.1038/sj.onc.1203650 · Cited by 276
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange, J., Prechtl, D., Cheburkin, Y. V., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., et al. (2002) · PubMed · Cited by 275
Identification of a new fibroblast growth factor receptor, FGFR5
Sleeman, M., Fraser, J., McDonald, M., Yuan, S., White, D., Grandison, P., Kumble, K., Watson, J. D., & Murison, J. G. (2001) · Gene · doi:10.1016/s0378-1119(01)00518-2 · Cited by 271
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
Pal, S. K., Rosenberg, J. E., Hoffman-Censits, J. H., Berger, R., Quinn, D. I., Galsky, M. D., Wolf, J., Dittrich, C., Keam, B., Delord, J.-P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0229 · Cited by 258
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38017 · Cited by 255
Ware, K. E., Hinz, T. K., Kleczko, E., Singleton, K. R., Marek, L. A., Helfrich, B. A., Cummings, C. T., Graham, D. K., Astling, D., Tan, A.-C., et al. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.4 · Cited by 249
8p11 myeloproliferative syndrome: a review
Jackson, C. C., Medeiros, L. J., & Miranda, R. N. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.11.003 · Cited by 247
Courjal, F., Cuny, M., Simony-Lafontaine, J., Louason, G., Speiser, P., Zeillinger, R., Rodríguez, C., & Theillet, C. G. (1997) · PubMed · Cited by 238
Xie, L., Su, X., Zhang, L., Yin, X., Tang, L., Zhang, X., Xu, Y., Gao, Z., Liu, K., Zhou, M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3898 · Cited by 237
Licitra, L., Mesia, R., Rivera, F., Remenár, É., Hitt, R., Erfán, J., Rottey, S., Kawecki, A., Zabolotnyy, D., Benasso, M., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq588 · Cited by 229
Mosaicism of activatingFGFR3 mutations in human skin causes epidermal nevi
Hafner, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28163 · Cited by 227
Terai, H., Soejima, K., Yasuda, H., Nakayama, S., Hamamoto, J., Arai, D., Ishioka, K., Ohgino, K., Ikemura, S., Sato, T., et al. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0652 · Cited by 206
Goriely, A., Hansen, R. M. S., Taylor, I. B., Olesen, I. A., Jacobsen, G. K., McGowan, S. J., Pfeifer, S. P., McVean, G. A. T., Meyts, E. R.-D., & Wilkie, A. O. M. (2009) · Nature Genetics · doi:10.1038/ng.470 · Cited by 205 · cited 2×
“FGFR3 mutations have also been identified in many other cancer types, including 3% of squamous cell lung carcinoma [23], cervical cancers [50], multiple myeloma [51], prostate cancer [52] and spermatocytic seminomas [53].”
BackgroundChronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Jabbour, E., & Kantarjian, H. (2016) · American Journal of Hematology · doi:10.1002/ajh.24275 · Cited by 183
Logié, A., Dunois-Lardé, C., Rosty, C., Levrel, O., Blanche, M., Ribeiro, A., Gasc, J.-M., Jorcano, J., Werner, S., Sastre-Garau, X., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi127 · Cited by 181
Tan, L., Wang, J., Tanizaki, J., Huang, Z., Aref, A. R., Rusan, M., Zhu, S.-J., Zhang, Y., Ercan, D., Liao, R. G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403438111 · Cited by 174
Self-citationGorringe, K. L., Jacobs, S., Thompson, E. R., Sridhar, A., Qiu, W., Choong, D. Y. H., & Campbell, I. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0502 · Cited by 171
Sharpe, R., Pearson, A., Herrera-Abreu, M. T., Johnson, D., Mackay, A., Welti, J. C., Natrajan, R., Reynolds, A. R., Reis-Filho, J. S., Ashworth, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2727 · Cited by 167
Freier, K., Schwaenen, C., Sticht, C., Flechtenmacher, C., Mühling, J., Hofele, C., Radlwimmer, B., Lichter, P., & Joos, S. (2007) · Oral Oncology · doi:10.1016/j.oraloncology.2006.01.005 · Cited by 165
Jabbour, E., Kantarjian, H., & Cortes, J. (2015) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2015.03.006 · Cited by 164
Characterization of a Novel Protein (FGFRL1) from Human Cartilage Related to FGF Receptors
Wiedemann, M., & Trueb, B. (2000) · Genomics · doi:10.1006/geno.2000.6332 · Cited by 163
Simon, R., Richter, J., Wagner, U. A., Fijan, A., Bruderer, J., Schmid, U., Ackermann, D., Maurer, R. E., Alund, G., Knönagel, H., et al. (2001) · PubMed · Cited by 162
Pardo, O. E., Latigo, J., Jeffery, R. E., Nye, E., Poulsom, R., Spencer-Dene, B., Lemoine, N. R., Stamp, G. W., Aboagye, E. O., & Seckl, M. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1576 · Cited by 160
Shea, M., Costa, D. B., & Rangachari, D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815617871 · Cited by 160
Neilson, K. M., & Friesel, R. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.40.25049 · Cited by 158
Zhang, J., Zhang, L., Su, X., Li, M., Xie, L., Malchers, F., Fan, S., Yin, X., Xu, Y., Liu, K., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2694 · Cited by 158
Wang, J., Stockton, D. W., & Ittmann, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0408 · Cited by 158
Wynes, M. W., Hinz, T. K., Gao, D., Martini, M., Marek, L. A., Ware, K. E., Edwards, M. G., Böhm, D., Perner, S., Helfrich, B. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3060 · Cited by 156
Biology of FGFRL1, the fifth fibroblast growth factor receptor
Trüeb, B. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0576-3 · Cited by 154
Bai, A., Meetze, K. A., Vo, N. N. Y., Kollipara, S., Mazsa, E. K., Winston, W. M., Weiler, S., Poling, L. L., Chen, T., Ismail, N. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1489 · Cited by 151
Paik, P. K., Shen, R., Berger, M. F., Ferry, D. R., Soria, J., Mathewson, A. M., Rooney, C., Smith, N. R., Cullberg, M., Kilgour, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0645 · Cited by 149
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 146
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E. N., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 143
FGFR3-TACC3 fusion in solid tumors: mini review
Costa, R. L. B., Carneiro, B. A., Taxter, T., Tavora, F. A., Kalyan, A., Pai, S. G., Chae, Y. K., & Giles, F. J. (2016) · Oncotarget · doi:10.18632/oncotarget.10482 · Cited by 142
Self-citationTakeda, M., Arao, T., Yokote, H., Komatsu, T., Yanagihara, K., Sasaki, H., Yamada, Y., Tamura, T., Fukuoka, K., Kimurâ, H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2743 · Cited by 136
Chen, Y., Li, X., Eswarakumar, V. P., Seger, R., & Lonai, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203726 · Cited by 135
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 132
Herrera-Abreu, M. T., Pearson, A., Campbell, J., Shnyder, S. D., Knowles, M. A., Ashworth, A., & Turner, N. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0569 · Cited by 132
LaVallee, T. M., Prudovsky, I. A., McMahon, G. A., Hu, X., & Maciag, T. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.7.1647 · Cited by 132
Angevin, E., Lopez-Martin, J. A., Lin, C., Gschwend, J. E., Harzstark, A. L., Castellano, D., Soria, J., Sen, P., Chang, J. E., Shi, M. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2885 · Cited by 129
Loss-of-Function Fibroblast Growth Factor Receptor-2 Mutations in Melanoma
Gartside, M. G., Chen, H., Ibrahimi, O. A., Byron, S. A., Curtis, A. V., Wellens, C. L., Bengston, A., Yudt, L. M., Eliseenkova, A. V., Ma, J., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0021 · Cited by 121
Martínez-Torrecuadrada, J., Cifuentes, G., Lopez-Serra, P., Sáenz, P., Martínez, A., & Casal, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0282 · Cited by 118
Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma
Capelletti, M., Dodge, M. E., Ercan, D., Hammerman, P. S., Park, S.-I., Kim, J., Sasaki, H., Jablons, D. M., Lipson, D., Young, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1337 · Cited by 118
Self-citationMilowsky, M. I., Dittrich, C., Durán, I., Jagdev, S., Millard, F. E., Sweeney, C. J., Bajorin, D. F., Cerbone, L., Quinn, D. I., Stadler, W. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.013 · Cited by 118
Thompson, L. M., Plummer, S. J., Schalling, M., Altherr, M. R., Gusella, J. F., Housman, D. E., & Wasmuth, J. J. (1991) · Genomics · doi:10.1016/0888-7543(91)90041-c · Cited by 115
Harmer, N. J., Ilag, L. L., Mulloy, B., Pellegrini, L., Robinson, C. V., & Blundell, T. L. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.04.031 · Cited by 109
Missiaglia, E., Selfe, J., Hamdi, M., Williamson, D., Schaaf, G., Fang, C., Köster, J., Summersgill, B. M., Messahel, B., Versteeg, R., et al. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20655 · Cited by 108
Li, S. Q., Cheuk, A., Shern, J. F., Song, Y., Hurd, L., Liao, H., Wei, J. S., & Khan, J. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076551 · Cited by 102
Turkington, R. C., Longley, D. B., Allen, W. L., Stevenson, L., McLaughlin, K., Dunne, P. D., Blayney, J. K., Salto-Tellez, M., Van Schaeybroeck, S., & Johnston, P. G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.10 · Cited by 98
Jung, E.-J., Jung, E., Min, S. Y., Kim, M. A., & Kim, W. H. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.002 · Cited by 98
Hierro, C., Rodon, J. A., & Tabernero, J. M. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.027 · Cited by 95
Chase, A., Grand, F., & Cross, N. C. P. (2007) · Blood · doi:10.1182/blood-2007-02-074286 · Cited by 92
Precision medicine in colorectal cancer: the molecular profile alters treatment strategies
Tran, N. H., Cavalcante, L. L., Lubner, S. J., Mulkerin, D. L., LoConte, N. K., Clipson, L. J., Matkowskyj, K. A., & Deming, D. A. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015591952 · Cited by 90
Göke, F., Franzen, A., Hinz, T. K., Marek, L. A., Yoon, P., Sharma, R. K., Bode, M., von Maessenhausen, A., Lankat–Buttgereit, B., Göke, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3357 · Cited by 89
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma
Keam, B., Kim, S., Shin, S. H., Cho, B. C., Lee, K., Kim, M. K., Yun, H., Lee, S., Yoon, D. H., & Bang, Y. (2015) · Cancer · doi:10.1002/cncr.29401 · Cited by 82
Sequist, L. V. D., Cassier, P. A., Varga, A., Tabernero, J. M., Schellens, J. H. M., Delord, J., LoRusso, P. M., Camidge, D. R., Medina, M. H., Schüler, M., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-ct326 · Cited by 78
FGFR3 mutations in prostate cancer: association with low-grade tumors
Hernandez, S. F., de Muga, S., Agell, L., Juanpere-Rodero, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S., & Lloreta, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.46 · Cited by 75
Wang, J., Mikse, O. R., Liao, R. G., Li, Y. Y., Tan, L., Janne, P. A., Gray, N. S., Wong, K., & Hammerman, P. S. (2014) · Oncogene · doi:10.1038/onc.2014.161 · Cited by 72
Self-citationSohl, C. D., Ryan, M. R., Luo, B., Frey, K. M., & Anderson, K. S. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00014 · Cited by 70
Hong, D. S., Kurzrock, R., Wheler, J. J., Naing, A., Falchook, G. S., Fu, S., Kim, K. B., Davies, M. A., Nguyen, L. M., George, G. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3063 · Cited by 70
High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer
Preusser, M., Berghoff, A. S., Berger, W., Ilhan‐Mutlu, A., Dinhof, C., Widhalm, G., Dieckmann, K. U., Wöehrer, A., Hackl, M., von Deimling, A., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.004 · Cited by 69
Differential Properties of Current Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Demetri, G. D. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.01.018 · Cited by 67
Vékony, H., Ylstra, B., Wilting, S. M., Meijer, G. A., van de Wiel, M. A., Leemans, C. R., van der Waal, I., & Bloemena, E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2555 · Cited by 63
Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy
Kim, S.-M., Kim, H.-D., Yun, M. R., Kang, H., Pyo, K.-H., Park, H. J., Lee, J. M., Choi, H., Ellinghaus, P., Ocker, M., et al. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.48 · Cited by 63
Bang, Y., Cutsem, E. V., Mansoor, W., Petty, R., Chao, Y., Cunningham, D., Ferry, D. R., Landers, D., Stockman, P. K., Smith, N. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4014 · Cited by 59
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Escudier, B. J., Grünwald, V., Ravaud, A., Ou, Y., Castellano, D., Lin, C., Gschwend, J. E., Harzstark, A. L., Beall, S., Pirotta, N., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3006 · Cited by 56
Javle, M. M., Shroff, R. T., Zhu, A. X., Sadeghi, S., Choo, S., Borad, M. J., Lowery, M. A., El-Khoueiry, A. B., Macarulla, T. M., Philip, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.335 · Cited by 55
Synergistic antitumor effects of FGFR2 inhibitor with 5‐fluorouracil on scirrhous gastric carcinoma
Yashiro, M., Shinto, O., Nakamura, K., Tendo, M., Matsuoka, T., Matsuzaki, T., Kaizaki, R., Miwa, A., & Hirakawa, K. (2009) · International Journal of Cancer · doi:10.1002/ijc.24763 · Cited by 53
Novel therapeutic targets in advanced urothelial carcinoma
Rouanne, M., Loriot, Y., Lebrét, T., & Soria, J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.021 · Cited by 53
Mellor, H. R. (2014) · Liver International · doi:10.1111/liv.12462 · Cited by 47
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells
Qiu, H., Yashiro, M., Zhang, X., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.015 · Cited by 47
Nishio, M., Horai, T., Horiike, A., Nokihara, H., Yamamoto, N., Takahashi, T., Murakami, H., Yamamoto, N., Koizumi, F., Nishio, K., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.374 · Cited by 47
Funato, N., Moriyama, K., Shimokawa, H., & Kuroda, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7588 · Cited by 44
Liu, X., Zhang, W., Geng, D., He, J., Zhao, Y., & Li, Y. (2014) · Genetics and Molecular Research · doi:10.4238/2014.february.20.12 · Cited by 44
Overcoming Resistance to Targeted Therapies in Cancer
Redmond, K. L., Papafili, A., Lawler, M., & Schaeybroeck, S. V. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.028 · Cited by 39
Maruyama‐Takahashi, K., Shimada, N., Imada, T., Maekawa‐Tokuda, Y., Ishii, T., Ouchi, J., Kusaka, H., Miyaji, H., Akinaga, S., Tanaka, A., et al. (2008) · The Prostate · doi:10.1002/pros.20728 · Cited by 38
Tchaicha, J. H., Akbay, E. A., Altabef, A. B., Mikse, O. R., Kikuchi, E., Rhee, K., Liao, R. G., Bronson, R. T., Sholl, L. M., Meyerson, M. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3218 · Cited by 37
Self-citationIdentification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Tanizaki, J., Ercan, D., Capelletti, M., Dodge, M. E., Xu, C., Bahcall, M., Tricker, E. M., Butaney, M., Calles, A., Sholl, L. M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3771 · Cited by 35
Self-citationLung-MAP--framework, overview, and design principles.
Ferrarotto, R., Redman, M. W., Gandara, D. R., Herbst, R. S., & Papadimitrakopoulou, V. A. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.09.02 · Cited by 32
Alorabi, M., Shonka, N., & Ganti, A. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.006 · Cited by 19
Standard chemotherapy with cetuximab for treatment of colorectal cancer
Li, X.-X., Liang, L., Huang, L.-Y., & Cai, S.-J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.7022 · Cited by 17
Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
Mak, G., Arkenau, H., & Chin, M. T. M. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000085 · Cited by 8
Cited by
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
The Role of Angiogenesis in Hepatocellular Carcinoma
Morse, M. A., Sun, W., Kim, R., He, A. R., Abada, P. B., Mynderse, M., & Finn, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1254 · Cited by 533
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
Haibe, Y., Kreidieh, M., El Hajj, H., Khalifeh, I., Mukherji, D., Temraz, S., & Shamseddine, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00221 · Cited by 396
Metadata
- Authors
- Chae, Y. K., Ranganath, K., Hammerman, P. S., Vaklavas, C., Mohindra, N., Kalyan, A., Matsangou, M., Costa, R., Carneiro, B., Villaflor, V. M., Cristofanilli, M., & Giles, F. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-12-22
- Volume
- 8
- Issue
- 9
- Pages
- 16052-16074
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2566505805
- Cited by
- 298
- References
- 123
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.